Outcomes of patients on dual-boosted PI regimens: Experience of the Swiss HIV Cohort study

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1239-1246

  Osih, Regina B ^a,i   Taffé, Patrick ^b   Rickenbach, Martin ^b   Gayet Ageron, Angèle ^c   Elzi, Luigia ^d   Fux, Christoph ^e   Opravil, Milos ^f   Bernasconi, Enos ^g   Schmid, Patrick ^h   Günthard, Huldrych F ^f   Cavassini, Matthias ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss HIV Cohort Study Data Center   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g Ospedale Regionale   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHOLESTEROL; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; HIGH DENSITY LIPOPROTEIN; LIPID; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SWITZERLAND; TREATMENT OUTCOME; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SALVAGE THERAPY; SWITZERLAND; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649275433     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0070     Document Type: Article

References (45)

1. Bartlett JA, Fath MJ, Demasi R, et al.: An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS 2006;20:2051-2064.
2. von Wyl V, Yerly S, Burgisser P, et al.: Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009;48:979-987.
3. Youle M, Staszweski S, Clotet B, et al.: Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: Recent data and consensus recommendations. HIV Clin Trials 2006;7:86-96.
4. Gallant JE. Protease-inhibitor boosting in the treatmentexperienced patient. AIDS Rev 2004;6:226-233.
5. Arnaiz JA, Mallolas J, Podzamczer D, et al.: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-840.
6. Boffito M, Maitland D, Samarasinghe Y, and Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 2005;18:1-7.
7. Kempf DJ, King MS, Bernstein B, et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
8. Voigt E, Wasmuth JC, Vogel M, et al.: Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. Infection 2004;32:82-88.
9. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis J 2008;47:266-285.
10. Hammer SM, Vaida F, Bennett KK, et al.: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 2002;288:169-180.
11. Hammer SM, Eron JJ, Jr., Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
12. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
13. von Wyl V, Yerly S, Boni J, et al.: Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008;46:1299-1309.
14. von Wyl V, Yerly S, Boni J, et al.: Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: A comparison of different regimen types. Arch Intern Med 2007;167:1782-1790.
15. Boffito M, Dickinson L, Hill A, et al.: Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;37:1376-1384.
16. Boffito M, Kurowski M, Kruse G, et al.: Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004;18:1291-1297.
17. Boffito M, Maitland D, Dickinson L, et al.: Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 2006;22:749-756.
18. Colombo S, Buclin T, Franc C, et al.: Ritonavir-boosted atazanavir-lopinavir combination: A pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther 2006;11:53-62.
19. Johnson M, Grinsztejn B, Rodriguez C, et al.: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694.
20. Ribera E, Azuaje C, Lopez RM, et al.: Atazanavir and lopinavir/ritonavir: Pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006;20:1131-1139.
21. Ribera E, Lopez RM, Diaz M, et al.: Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48:4256-4262.
22. Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
23. Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, and Redfield RR. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDS 2006;20:745-759.
24. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 2006;14:827-843.
25. Collier AC, Tierney C, Downey GF, et al.: Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor- experienced patients with HIV. HIV Clin Trials 2008;9:91-102.
26. Gupta R, Hill A, Sawyer AW, and Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis 2008;47:712-722.
27. Hosseinipour M. Resistance profile of patients failing first line ART in Malawi when using clinical and immunologic monitoring. Paper presented at: Seventeenth International AIDS Conference, 2008; Mexico City.
28. Gupta RHA, Sawyer A, Cozzi-Lepri A, et al.: The intensity of virological monitoring is associated with resistance to first line HAART in HIV-1 infected adults under the WHO public health approach to antiretroviral therapy: A systematic analysis of cohort and trial data. Lancet Infect Dis 2009;9:409-417.
29. Ledergerber B, von Overbeck J, Egger M, and Luthy R. The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics. Soz Praventivmed 1994;39:387-394.
30. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, and Francioli P. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000;130:1493-1500.
31. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, and Moore RD. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007;45:515-520.
32. Grinsztejn B, Nguyen BY, Katlama C, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007;369:1261-1269.
33. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
34. Molina JM, Cohen C, Katlama C, et al.: Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatmentexperienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24-31. (Pubitemid 47514614)
35. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, and Kashuba AD. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004;36:921-928.
36. la Porte CJ, Wasmuth JC, Schneider K, Rockstroh JK, and Burger DM. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003;17:1700-1702.
37. Smith GH, Boulassel MR, Klien M, et al.: Virologic and immunologic response to a boosted double-protease inhibitorbased therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials 2005;6:63-72.
38. Stebbing J, Scourfield A, Koh G, et al.: A multicentre cohort experience with double-boosted protease inhibitors. J Antimicrob Chemother 2009;64:434-435.
39. Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, and Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 2007;21:1547-1554.
40. Loutfy M, Raboud J, Thompson C, et al.: Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials 2003;4:301-310.
41. Kosalaraksa P, Bunupuradah T, Engchanil C, et al.: Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008;27:623-628.
42. Ananworanich J, Kosalaraksa P, Hill A, et al.: Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005;24:874-879.
43. Ribera E and Curran A. Double-boosted protease inhibitor antiretroviral regimens: What role? Drugs 2008;68:2257-2267.
44. Glass TR, De Geest S, Hirschel B, et al.: Self-reported nonadherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008;13:77-85.
45. Boni J, Pyra H, Gebhardt M, et al.: High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr 1999;22:174-179.